Researchers analyzed existing studies to see if a common type of heart medication helps people after they have a TAVR procedure. TAVR is a minimally invasive way to replace a narrowed aortic valve. The analysis combined data from 12 studies involving over 35,000 patients, most of whom were in their late 70s to early 80s. They compared patients who took renin-angiotensin system (RAS) inhibitor drugs after TAVR to those who did not.
The main finding was that taking these medications was linked to better outcomes. The analysis calculated a 99.5% probability that the drugs were associated with a meaningful reduction in death from heart-related causes. There was also a 79.4% probability they were linked to lower risk of death from any cause, and a 54% probability they were linked to fewer hospitalizations for heart failure. The analysis found almost no link to a reduced risk of heart attack.
It is very important to understand what this study does and does not tell us. This was a meta-analysis, which means it re-examined data from other, mostly observational, studies. Observational studies can show a link, but they cannot prove that the medication caused the better outcomes. The researchers reported probabilities of benefit, not the actual size of the benefit or how many people were helped. The analysis also did not report on medication side effects or safety. Patients should not start or stop any heart medication based on this analysis alone. Anyone with questions about their medications after a TAVR should talk with their cardiologist.
